Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate
Many people who dedicate their lives to discovering, developing, and making new, lifesaving drugs don’t understand the extent to which the drug industry has failed to communicate its value proposition to society and to inspire its customers to pay for that value. That is to say, when the public and even legislators representing our biotech innovation hubs focus on the price of a breakthrough drug without a sense of its value or how it came into being and insist that innovators should not only invent medicines but pay for them, too, that’s a self-inflicted wound. Vertex’s Trikafta, one of our industry’s greatest success stories, provides an example.
Battling the consequences of price controls at high altitude
As a pioneering PDAB takes its first baby steps in Colorado, we’re getting the impression that we’re watching the rules being made up as it goes along. Fortunately, we’re also witnessing the power of organized and impassioned patient advocacy to slow, reverse, and maybe someday reshape misinformed public policy.
RA TV: How do we determine what a drug is worth?
In this month’s episode, we discuss the latest COVID news. Then Peter Kolchinsky talks with our guest, Dr. Joshua Cohen of Tufts Medical Center, about how they estimate the value of a drug.
What happens if President Biden’s drug pricing plan passes?
If the Biden drug plan passes, the United States will be consciously volunteering to put less capital to work in a large industry where we lead the world. No real argument can stand against the fact that less capital means fewer new products for patients.
Biotechnology leadership is too valuable to throw away
The U.S. biotechnology sector is an indispensable, strategic national asset. But what if we’re taking it for granted? Recent attempts to weaken IP protections for Covid-19 vaccines and to implement drug price controls threaten future U.S. leadership in biotechnology.
When drug prices are a Trojan Horse for other costs, we all lose
The way that hospitals benefit from inflated list prices is a common theme across different kinds of drugs dispensed at hospitals and clinics across the country. When drug prices are a Trojan Horse for all kinds of other health care costs, we all lose.